|Bid||2.76 x 300|
|Ask||3.00 x 17600|
|Day's Range||2.84 - 2.96|
|52 Week Range||1.96 - 3.55|
|PE Ratio (TTM)||4.03|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PDL BioPharma (PDLI) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
The Incline Village, Nevada-based company said it had net income of 15 cents per share. Earnings, adjusted for one-time gains and costs, were 17 cents per share. The biotechnology company posted revenue ...
PDL BioPharma Inc’s (NASDAQ:PDLI) most recent return on equity was a substandard 9.49% relative to its industry performance of 17.87% over the past year. Though PDLI’s recent performance is underwhelming,Read More...
There were some huge moves in the biotech space in the past week, with Portola Pharmaceuticals Inc (NASDAQ: PTLA ) slumping over 25 percent on perceived FDA risk after the company said the FDA may mandate ...
PDL BioPharma Inc (NASDAQ:PDLI) trades with a trailing P/E of 5x, which is lower than the industry average of 28.5x. Although some investors may jump to the conclusion that thisRead More...
You'll probably be surprised by some of the stock picks from a leading artificial-intelligence system.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to PDL BioPharma, Inc. Here are 5 ETFs with the largest exposure to PDLI-US. Comparing the performance and risk of PDL BioPharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis PDL BioPharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of PDL BioPharma, Inc. – Compugen Ltd., Nektar Therapeutics, BioTime, Inc., Mylan N.V., Amgen Inc., Eli Lilly and Company and Sangamo Therapeutics, Inc. (CGEN-US, NKTR-US, BTX-US, MYL-US, AMGN-US, LLY-US ... Read more (Read more...)
AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.
The Incline Village, Nevada-based company said it had profit of 14 cents per share. Earnings, adjusted for one-time gains and costs, came to 15 cents per share. The biotechnology company posted revenue ...
U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc, will consider offers from other potential buyers, according to people familiar with the matter. Neos, a developer of attention deficit disorder treatments, rejected, as inadequate, a nearly $300 million all-cash bid from PDL that was more than a 40 percent premium to its market value. PDL could clinch a deal if it were to offer a higher price, the sources added, cautioning that there was no certainty of any transaction.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives PDL BioPharma, Inc. a score of 53. Our analysis is based on comparing PDL BioPharma, Inc. with the following peers – Compugen Ltd., Nektar Therapeutics, BioTime, Inc., Mylan N.V., Amgen Inc., Eli Lilly and Company, Enzon Pharmaceuticals, Inc. and Sangamo Therapeutics, Inc. (CGEN-US, NKTR-US, BTX-US, MYL-US, AMGN-US, ... Read more (Read more...)
Neos Therapeutics Inc (NASDAQ:NEOS) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 37% upturn. The reason? PDL BioPharma (NASDAQ:PDLI) made a hostile bid to acquire Neos for $10.25 share in cash (40% upside from yesterday's close). PDL first formally proposed to acquire Neos on June 23, 2017, but Neos' board rejected the offer.
Pharmaceutical company Neos received an offer for $10.25 per share, which would value the deal around $288 million. It's the third time PDL has tried to make a deal.